Table of Contents

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended November 30, 2011

 

 

o

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

 

For the transition period from                  to                  

 

Commission file number 000-23425

 

Burzynski Research Institute, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware

 

76-0136810

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

 

9432 Old Katy Road, Suite 200, Houston, Texas 77055

(Address of principal executive offices)

 

(713) 335-5697

(Registrant’s telephone number)

 

 

(Former name, former address, and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definition of “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large accelerated filer o

 

Accelerated filer o

 

 

 

Non-accelerated filer o

 

Smaller reporting company x

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes o No x

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:  As of November 30, 2011, 131,448,444 shares of the Registrant’s Common Stock were outstanding.

 

 

 



Table of Contents

 

BURZYNSKI RESEARCH INSTITUTE, INC.

 

Form 10-Q

 

Table of Contents

 

PART I — FINANCIAL INFORMATION

 

 

 

 

 

Item 1.

Financial Statements

3

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

9

 

 

 

 

 

Item 4.

Controls and Procedures

11

 

 

 

 

PART II — OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

12

 

 

 

 

 

Item 6.

Exhibits

12

 

2



Table of Contents

 

Item 1.   Financial Statements

 

BURZYNSKI RESEARCH INSTITUTE, INC.

BALANCE SHEETS

 

 

 

November 30,

 

February 28,

 

 

 

2011

 

2011

 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

 

$

16,134

 

$

17,476

 

TOTAL CURRENT ASSETS

 

16,134

 

17,476

 

 

 

 

 

 

 

Property and equipment, net of accumulated depreciation of $18,826 and $18,295 at November 30, 2011 and February 28, 2011, respectively

 

3,589

 

4,120

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

19,723

 

$

21,596

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

 

$

3,585

 

$

39,223

 

Accrued liabilities

 

43,993

 

33,628

 

CURRENT AND TOTAL LIABILITIES

 

47,578

 

72,851

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

Stockholders’ deficit

 

 

 

 

 

Common stock, $.001 par value; 200,000,000 shares authorized, 131,448,444 issued and outstanding at November 30, 2011 and February 28, 2011, respectively

 

131,449

 

131,449

 

Additional paid-in capital

 

99,410,009

 

94,260,707

 

Retained deficit

 

(99,569,313

)

(94,443,411

)

 

 

 

 

 

 

TOTAL STOCKHOLDERS’ DEFICIT

 

(27,855

)

(51,255

)

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

$

19,723

 

$

21,596

 

 

See accompanying notes to financial statements.

 

3



Table of Contents

 

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)

 

 

 

Three Months Ended

 

 

 

November 30,

 

 

 

2011

 

2010

 

Operating expenses

 

 

 

 

 

Research and development

 

$

1,764,352

 

$

1,172,273

 

General and administrative

 

75,451

 

37,220

 

Depreciation

 

177

 

180

 

Total operating expenses

 

1,839,980

 

1,209,673

 

 

 

 

 

 

 

Net loss before provision for income tax

 

(1,839,980

)

(1,209,673

)

 

 

 

 

 

 

Provision for income tax

 

 

 

 

 

 

 

 

 

NET LOSS

 

$

(1,839,980

)

$

(1,209,673

)

 

 

 

 

 

 

Loss per share information:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$

(0.01

)

$

(0.01

)

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

131,448,444

 

131,448,444

 

 

 

 

Nine Months Ended

 

 

 

November 30,

 

 

 

2011

 

2010

 

Operating expenses

 

 

 

 

 

Research and development

 

$

4,939,748

 

$

3,592,998

 

General and administrative

 

185,623

 

195,996

 

Depreciation

 

531

 

552

 

Total operating expenses

 

5,125,902

 

3,789,546

 

 

 

 

 

 

 

Net loss before provision for income tax

 

(5,125,902

)

(3,789,546

)

 

 

 

 

 

 

Provision for income tax

 

 

 

 

 

 

 

 

 

NET LOSS

 

$

(5,125,902

)

$

(3,789,546

)

 

 

 

 

 

 

Loss per share information:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$

(0.04

)

$

(0.03

)

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

131,448,444

 

131,448,444

 

 

See accompanying notes to financial statements.

 

4



Table of Contents

 

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENT OF STOCKHOLDERS’ DEFICIT

For the Nine Months Ended November 30, 2011

(UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

Additional

 

 

 

Stockholders’

 

 

 

Shares

 

Amount

 

Paid-in Capital

 

Retained Deficit

 

Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance February 28, 2011

 

131,448,444

 

$

131,449

 

$

94,260,707

 

$

(94,443,411

)

$

(51,255

)

 

 

 

 

 

 

 

 

 

 

 

 

Cash contributed by S.R. Burzynski, M.D., Ph.D.

 

 

 

387,199

 

 

387,199

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.

 

 

 

4,762,103

 

 

4,762,103

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

(5,125,902

)

(5,125,902

)

 

 

 

 

 

 

 

 

 

 

 

 

Balance November 30, 2011

 

131,448,444

 

$

131,449

 

$

99,410,009

 

$

(99,569,313

)

$

(27,855

)

 

See accompanying notes to financial statements.

 

5



Table of Contents

 

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

 

Nine Months Ended November 30,

 

 

 

2011

 

2010

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

Net loss

 

$

(5,125,902

)

$

(3,789,546

)

Adjustments to reconcile net loss to net cash used by operating activities:

 

 

 

 

 

Depreciation

 

531

 

552

 

FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.

 

4,762,103

 

3,411,767

 

Changes in operating assets and liabilities

 

 

 

 

 

Accounts payable

 

(35,638

)

(22,609

)

Accrued liabilities

 

10,365

 

(12

)

 

 

 

 

 

 

NET CASH USED BY OPERATING ACTIVITIES

 

(388,541

)

(399,848

)

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

Contribution of capital

 

387,199

 

398,829

 

 

 

 

 

 

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

 

387,199

 

398,829

 

 

 

 

 

 

 

NET DECREASE IN CASH

 

(1,342

)

(1,019

)

 

 

 

 

 

 

CASH AT BEGINNING OF PERIOD

 

17,476

 

18,122

 

 

 

 

 

 

 

CASH AT END OF PERIOD

 

$

16,134

 

$

17,103

 

 

See accompanying notes to financial statements

 

6


 


Table of Contents

 

BURZYNSKI RESEARCH INSTITUTE, INC.

NOTES TO FINANCIAL STATEMENTS

 

NOTE A.      BASIS OF PRESENTATION

 

The financial statements of Burzynski Research Institute, Inc., a Delaware corporation (the “Company”), include expenses incurred directly by S.R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) within his medical practice, related to the conduct of U.S. Food and Drug Administration (“FDA”) approved clinical trials for Antineoplaston drugs used in the treatment of cancer.  These expenses have been reported as research and development costs and as additional paid-in capital.  Cash contributions received from Dr. Burzynski have also been reported as additional paid-in capital, which are used to fund general operating expenses. Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements.  Dr. Burzynski is the President, Chairman of the Board and owner of over 80% of the outstanding stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons,” which he has licensed to the Company.

 

The Company and Dr. Burzynski have entered into various agreements which provide the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once an Antineoplaston drug is approved for sale by the FDA.

 

The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.  The Company is currently conducting clinical trials on various Antineoplastons in accordance with FDA regulations. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted. In September 2004, the Company announced that the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of brainstem glioma.  During 2008, the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of all gliomas.

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2011 and February 28, 2011, results of operations for the three and nine months ended November 30, 2011 and 2010, and cash flows for the nine months ended November 30, 2011 and 2010.  All adjustments are of a normal recurring nature.  The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.  These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2011.

 

NOTE B.      ECONOMIC DEPENDENCY

 

The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit.  Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.

 

The Company is economically dependent on its funding through Dr. Burzynski’s medical practice.  A portion of Dr. Burzynski’s patients are admitted and treated as part of the clinical trial programs, which are regulated by the FDA.  The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA.  These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA.

 

In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.

 

It is also the intention of the directors and management to seek additional capital through the sale of securities.  The proceeds from such sales will be used to fund the Company’s operating deficit until it achieves positive operating cash flow.  There can be no assurance that the Company will be able to raise such additional capital.

 

7



Table of Contents

 

NOTE C.      STOCK OPTIONS

 

At November 30, 2011, the Company had one stock-based employee compensation plan, which is described below.

 

On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company.  The options vested as follows:

 

400,000 options

 

September 14, 1996

100,000 options

 

June 1, 1997

100,000 options

 

June 1, 1998

 

The options are valid in perpetuity.  In addition, for a period of 10 years from the grant date, they increase in the same percentage of any new shares of stock issued; however, no shares were issued during such 10-year periods from the grant dates.  None of the options have been exercised as of November 30, 2011.

 

The Company follows the fair value recognition provisions of FASB ASC 718, “Compensation — Stock Compensation.” Under this method, compensation cost for all share-based payments is based on the grant-date fair value and amortized to expense over the requisite service period, generally the vesting period.

 

The Company did not grant any options and no options previously granted vested in any of the periods presented in these financial statements.  Due to this fact, there was no effect on net loss and loss per share.

 

NOTE D.      INCOME TAXES

 

The Company follows the provisions of FASB ASC 740-10, “Accounting for Uncertainty in Income Taxes.”  The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.

 

The Company recognizes interest and penalties as interest expense when they are accrued or assessed.

 

The federal income tax returns of the Company for 2010, 2009, and 2008 are subject to examination by the IRS, generally for three years after they are filed.

 

The actual provision for income tax for the three months and nine months ended November 30, 2011 and 2010, respectively, differ from the amounts computed by applying the U.S. federal income tax rate of 34% to the pretax loss as a result of the following:

 

 

 

Three Months Ended November 30,

 

 

 

2011

 

2010

 

 

 

 

 

 

 

Expected income tax benefit

 

$

(625,594

)

$

(411,289

)

Effect of expenses deducted directly by Dr. Burzynski

 

625,594

 

411,289

 

Nondeductible expenses and other adjustments

 

6,018

 

(26,672

)

Change in valuation allowance

 

(6,018

)

26,672

 

State tax

 

 

 

 

 

 

 

 

 

Income tax expense

 

$

 

$

 

 

 

 

Nine Months Ended November 30,

 

 

 

2011

 

2010

 

 

 

 

 

 

 

Expected income tax benefit

 

$

(1,742,807

)

$

(1,288,446

)

Effect of expenses deducted directly by Dr. Burzynski

 

1,742,807

 

1,288,442

 

Nondeductible expenses and other adjustments

 

(7,955

)

(7,157

)

Change in valuation allowance

 

7,955

 

7,161

 

State tax

 

 

 

 

 

 

 

 

 

Income tax expense

 

$

 

$

 

 

8



Table of Contents

 

At November 30, 2011, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $365,723.  The Company’s ability to utilize net operating loss carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income.  The Company has no historical earnings on which to base an expectation of future taxable income.  Accordingly, a valuation allowance for deferred tax assets has been provided.  At November 30, 2011, the Company had net operating loss carryforwards available to offset future income in the amount of $934,925, which may be carried forward and will expire if not used between 2012 and 2032 in varying amounts.

 

Item 2.           Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following is a discussion of the financial condition of the Company as of November 30, 2011, and the results of operations comparing the three and nine months ended November 30, 2011 and 2010.  It should be read in conjunction with the financial statements and the notes thereto included elsewhere in this report and in conjunction with the Annual Report on Form 10-K for the year ended February 28, 2011.

 

Introduction

 

The Company was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name “Antineoplastons.”  The Company believes Antineoplastons are useful in the treatment of human cancer and is currently conducting Phase II clinical trials of Antineoplastons relating to the treatment of cancer.  The Company has generated no significant revenue since its inception, and does not expect to generate any operating revenues until such time, if any, as Antineoplastons are approved for use and sale by the FDA.  The Company’s sole source of funding is S.R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”), the Company’s President and Chief Executive Officer.  Dr. Burzynski funds the Company’s operations from his medical practice pursuant to certain agreements between Dr. Burzynski and the CompanyFunds received by the Company from Dr. Burzynski are reported as additional paid-in capital to the Company.

 

The Company is primarily engaged as a research and development facility of drugs currently being tested for the use in the treatment of cancer, and provides consulting services.  The Company is currently conducting two FDA-approved clinical trials.  The Company holds the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment and diagnosis of cancer, once an Antineoplaston drug is approved for sale by the FDA.

 

In September 2004, the Company announced that the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for treating patients with brainstem gliomas.  During 2008, the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of all gliomas.

 

On January 13, 2009, the Company announced that the Company had reached an agreement with the FDA for the Company to move forward with a pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed, diffuse, intrinsic brainstem gliomas (“DBSG”).  The agreement was made under the FDA’s Special Protocol Assessment procedure, meaning that the design and planned analysis of the Phase III study is acceptable to support a regulatory submission seeking new drug approval.  On February 1, 2010, the Company entered into an agreement with Cycle Solutions, Inc., dba ResearchPoint (“ResearchPoint”) to initiate and manage a pivotal Phase III clinical trial of combination Antineoplastons A10 and AS2-1 plus radiation therapy (RT) in patients with newly-diagnosed DBSG.  ResearchPoint has secured interest and commitments from a number of sites selected.  Upon completion of this assessment, a randomized, international phase III study will commence.  The study’s objective is to compare overall survival of children with newly-diagnosed DBSG who receive combination Antineoplastons A10 and AS2-1 plus RT versus RT alone.

 

Results of Operations

 

Three Months Ended November 30, 2011 Compared to Three Months Ended November 30, 2010

 

Research and development costs were approximately $1,764,000 and $1,172,000 for the three months ended November 30, 2011 and 2010, respectively.  The increase of $592,000 or 51% was due to increases in personnel costs of $103,000, material costs of $515,000, facility and equipment costs of $9,000, offset by decreases in consulting and quality control costs of $26,000, and other research and developments costs of $9,000.

 

General and administrative expenses were approximately $75,000 and $37,000 for the three months ended November 30, 2011 and 2010, respectively.  The increase of $38,000 or 103% was due to increases in legal and professional fees of $37,000, and other general and administrative expenses of $1,000.

 

9



Table of Contents

 

The Company had net losses of approximately $1,840,000 and $1,210,000 for the three months ended November 30, 2011 and 2010, respectively.  The increase in the net loss from 2010 to 2011 is primarily due to the increases in research and development costs due to increased personnel costs, material costs, and facility and equipment costs, offset by decreases in consulting and quality control costs and other research and development costs, and additional increases in general and administrative expenses due to increased legal and professional fees and other general and administrative costs.

 

Nine Months Ended November 30, 2011 Compared to Nine Months Ended November 30, 2010

 

Research and development costs were approximately $4,940,000 and $3,593,000 for the nine months ended November 30, 2011 and 2010, respectively.  The increase of $1,347,000 or 37% was due to increases in personnel costs of $104,000, material costs of $1,195,000, and facility and equipment costs of $55,000, offset by decreases in other research and developments costs of $7,000.

 

General and administrative expenses were approximately $186,000 and $196,000 for the nine months ended November 30, 2011 and 2010, respectively.  The decrease of $10,000 or 5% was due to decreases in legal and professional fees of $6,000, and other general and administrative expenses of $4,000.

 

The Company had net losses of approximately $5,126,000 and $3,790,000 for the nine months ended November 30, 2011 and 2010, respectively.  The increase in the net loss from 2010 to 2011 is primarily due to the increases in research and development costs due to increases in personnel costs, material costs, and facility and equipment costs, offset by decreases in other research and development costs, offset by decreases in general and administrative expenses due to decreases in legal and professional fees and other general and administrative costs.

 

Liquidity and Capital Resources

 

The Company’s operations have been funded entirely by contributions from Dr. Burzynski and from funds generated from Dr. Burzynski’s medical practice.  Effective March 1, 1997, the Company entered into a Research Funding Agreement with Dr. Burzynski (the “Research Funding Agreement”), pursuant to which the Company agreed to undertake all scientific research in connection with the development of new or improved Antineoplastons for the treatment of cancer and Dr. Burzynski agreed to fund the Company’s Antineoplaston research for that purpose.  Under the Research Funding Agreement, the Company hires such personnel as is required to conduct Antineoplaston research, and Dr. Burzynski funds the Company’s research expenses, including expenses to conduct the clinical trials.  Dr. Burzynski also provides the Company laboratory and research space as needed to conduct the Company’s research activities.  The Research Funding Agreement also provides that Dr. Burzynski may fulfill his funding obligations in part by providing the Company such administrative support as is necessary for the Company to manage its business.  Dr. Burzynski pays the full amount of the Company’s monthly and annual budget of expenses for the operation of the Company, together with other unanticipated but necessary expenses which the Company incurs.  In the event the research results in the approval of any additional patents for the treatment of cancer, Dr. Burzynski shall own all such patents, but shall license to the Company the patents based on the same terms, conditions and limitations as are in the current license between Dr. Burzynski and the Company.

 

The amounts which Dr. Burzynski is obligated to pay under the agreement shall be reduced dollar for dollar by the following: (1) any income which the Company receives for services provided to other companies for research and/or development of other products, less such identifiable marginal or additional expenses necessary to produce such income, or (2) the net proceeds of any stock offering or private placement which the Company receives during the term of the agreement up to a maximum of $1,000,000 in a given Company fiscal year.

 

The Research Funding Agreement, as amended, contains an annual automatic renewal provision providing for an additional one-year term, unless one party notifies the other party at least thirty days prior to the expiration of the then current term of the agreement of its intention not to renew the agreement.  Subject to the foregoing, the term of the Research Funding Agreement was renewed and extended until February 29, 2012.  It is expected that the Research Funding Agreement will continue to renew each year prospectively unless terminated under the provisions of the agreement.

 

The Research Funding Agreement automatically terminates in the event that Dr. Burzynski owns less than fifty percent of the outstanding shares of the Company, or is removed as President and/or Chairman of the Board of the Company, unless Dr. Burzynski notifies the Company in writing of his intention to continue the agreement notwithstanding this automatic termination provision.

 

10



Table of Contents

 

The Company estimates that it will spend approximately $1,800,000 during the remaining quarter of the fiscal year ending February 29, 2012.  The Company estimates that ninety-five percent (95%) of this amount will be spent on research and development and the continuance of FDA-approved clinical trials.  While the Company anticipates that Dr. Burzynski will continue to fund the Company’s research and FDA-related costs, there is no assurance that Dr. Burzynski will be able to continue to fund the Company’s operations pursuant to the Research Funding Agreement or otherwise.  The Company believes Dr. Burzynski will be financially able to fund the Company’s operations for at least the next year.  In addition, Dr. Burzynski’s medical practice has successfully funded the Company’s research activities over the last 25 years and, in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene-targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials.  As a result of the expansion of Dr. Burzynski’s medical practice, the financial condition of the medical practice has improved Dr. Burzynski’s ability to fund the Company’s operations.

 

The Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company.  In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.

 

Forward-Looking Statements

 

Certain matters discussed in this quarterly report, except for historical information contained herein, may constitute “forward-looking statements” that are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking statements provide current expectations of future events based on certain assumptions.  These statements encompass information that does not directly relate to any historical or current fact and often may be identified with words such as “anticipates,” “believes,” “expects,” “estimates,” “intends,” “plans,” “projects” and other similar expressions.  Management’s expectations and assumptions regarding Company operations and other future results are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements.

 

Item 4.           Controls and Procedures

 

Within the 90 days prior to the date of this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer (who is also the Company’s principal financial officer), of the effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-14 under the Securities Exchange Act of 1934, as amended.  Based on that evaluation, the Company’s principal executive officer (who is also the Company’s principal financial officer) concluded that the Company’s disclosure controls and procedures are effective in timely alerting him to material information required to be included in periodic filings with the Securities and Exchange Commission.  A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.  There were no significant changes in the Company’s internal controls or in other factors that could significantly affect internal controls over financial reporting that occurred during the fiscal quarter ended November 30, 2011 that have materially affected or are reasonably likely to materially affect our internal controls subsequent to that date.

 

11



Table of Contents

 

PART II — OTHER INFORMATION

 

Item 1.           Legal Proceedings

 

The Company’s activities are subject to regulation by various governmental agencies, including the FDA, which regularly monitor the Company’s operations and often impose requirements on the conduct of its clinical trials and other aspects of the Company’s business operations.  The Company’s policy is to comply with all such regulatory requirements.  From time to time, the Company is also subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The Company seeks to minimize its exposure to claims of this type wherever possible.

 

Currently, the Company is not a party to any material pending legal proceedings.  Moreover, the Company is not aware of any such legal proceedings that are contemplated by governmental authorities with respect to the Company or any of its properties.

 

Item 6.   Exhibits

 

 

3.1

 

Certificate of Incorporation of the Company, as amended (incorporated by reference from Exhibits 3(i) — (iii) to Form 10-SB filed with the Securities and Exchange Commission on November 25, 1997 (File No. 000-23425)).

 

 

 

 

 

3.2

 

Amended Bylaws of the Company (incorporated by reference from Exhibit 3(iv) to Form 10-SB filed with the Securities and Exchange Commission on November 25, 1997 (File No. 000-23425)).

 

 

 

 

 

31.1

 

Certification of Chief Executive Officer and Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as amended, filed herewith.

 

 

 

 

 

32.1

 

Certification of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

 

12



Table of Contents

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BURZYNSKI RESEARCH INSTITUTE, INC.

 

 

 

 

By:

/s/ Stanislaw R. Burzynski

 

 

Stanislaw R. Burzynski,

 

 

President, Secretary, Treasurer and

 

 

Chairman of the Board of Directors

 

 

(Chief Executive Officer and

 

 

Principal Financial Officer)

 

Date: January 17, 2012

 

13


 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULES 13a-14 AND 15d-14
OF THE SECURITIES EXCHANGE ACT OF 1934
(Section 302 of the Sarbanes-Oxley Act of 2002)

 

I, Stanislaw R. Burzynski, certify that:

 

1.             I have reviewed this quarterly report on Form 10-Q of Burzynski Research Institute, Inc. (“BRI”);

 

2.             Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.             Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of BRI as of, and for, the periods presented in this quarterly report;

 

4.             I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for BRI and have:

 

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to BRI is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)           Designated such internal control over financial reporting, or caused such internal control over financial reporting to be designated under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)           Evaluated the effectiveness of BRI’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

 

(d)           Disclosed in this quarterly report any change in BRI’s internal control over financial reporting that occurred during BRI’s most recent fiscal quarter (BRI’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, BRI’s internal control over financial reporting; and

 

5.             I have disclosed, based on our most recent evaluation of internal control over financial reporting, to BRI’s auditors and the audit committee of BRI’s board of directors (or persons performing the equivalent functions of an audit committee):

 

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect BRI’s ability to record, process, summarize and report financial information; and

 

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in BRI’s internal control over financial reporting.

 

Date: January 17, 2012

 

/s/ Stanislaw R. Burzynski

 

 

Stanislaw R. Burzynski,

 

 

President, Secretary, Treasurer and

 

 

Chairman of the Board of Directors

 

 

(Chief Executive Officer and

 

 

Principal Financial Officer)

 


 

EXHIBIT 32.1

 

Certification of Chief Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. § 1350
(Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with the Quarterly Report of Burzynski Research Institute, Inc. (the “Company”) on Form 10-Q for the period ended November 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)           The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Burzynski Research Institute, Inc. and will be retained by Burzynski Research Institute, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: January 17, 2012

 

 

 

 

 

 

 

/s/ Stanislaw R. Burzynski

 

 

Stanislaw R. Burzynski

 

 

President, Secretary, Treasurer

 

 

and Chairman of the Board of Directors

 

 

(Chief Executive Officer and

 

 

Principal Financial Officer)

 


 

v2.4.0.6
STOCK OPTIONS
9 Months Ended
Nov. 30, 2011
STOCK OPTIONS  
STOCK OPTIONS

NOTE C.      STOCK OPTIONS

 

At November 30, 2011, the Company had one stock-based employee compensation plan, which is described below.

 

On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company.  The options vested as follows:

 

400,000 options

 

September 14, 1996

100,000 options

 

June 1, 1997

100,000 options

 

June 1, 1998

 

The options are valid in perpetuity.  In addition, for a period of 10 years from the grant date, they increase in the same percentage of any new shares of stock issued; however, no shares were issued during such 10-year periods from the grant dates.  None of the options have been exercised as of November 30, 2011.

 

The Company follows the fair value recognition provisions of FASB ASC 718, “Compensation — Stock Compensation.” Under this method, compensation cost for all share-based payments is based on the grant-date fair value and amortized to expense over the requisite service period, generally the vesting period.

 

The Company did not grant any options and no options previously granted vested in any of the periods presented in these financial statements.  Due to this fact, there was no effect on net loss and loss per share.

v2.4.0.6
ECONOMIC DEPENDENCY
9 Months Ended
Nov. 30, 2011
ECONOMIC DEPENDENCY  
ECONOMIC DEPENDENCY

NOTE B.      ECONOMIC DEPENDENCY

 

The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit.  Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.

 

The Company is economically dependent on its funding through Dr. Burzynski’s medical practice.  A portion of Dr. Burzynski’s patients are admitted and treated as part of the clinical trial programs, which are regulated by the FDA.  The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA.  These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA.

 

In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice.  The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.

 

It is also the intention of the directors and management to seek additional capital through the sale of securities.  The proceeds from such sales will be used to fund the Company’s operating deficit until it achieves positive operating cash flow.  There can be no assurance that the Company will be able to raise such additional capital.

v2.4.0.6
BALANCE SHEETS (USD $)
Nov. 30, 2011
Feb. 28, 2011
Current assets    
Cash and cash equivalents $ 16,134 $ 17,476
TOTAL CURRENT ASSETS 16,134 17,476
Property and equipment, net of accumulated depreciation of $18,826 and $18,295 at November 30, 2011 and February 28, 2011, respectively 3,589 4,120
TOTAL ASSETS 19,723 21,596
Current liabilities    
Accounts payable 3,585 39,223
Accrued liabilities 43,993 33,628
CURRENT AND TOTAL LIABILITIES 47,578 72,851
Commitments and contingencies      
Stockholders' deficit    
Common stock, $.001 par value; 200,000,000 shares authorized, 131,448,444 issued and outstanding at November 30, 2011 and February 28, 2011, respectively 131,449 131,449
Additional paid-in capital 99,410,009 94,260,707
Retained deficit (99,569,313) (94,443,411)
TOTAL STOCKHOLDERS' DEFICIT (27,855) (51,255)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 19,723 $ 21,596

v2.4.0.6
STATEMENTS OF CASH FLOWS (USD $)
9 Months Ended
Nov. 30, 2011
Nov. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (5,125,902) $ (3,789,546)
Adjustments to reconcile net loss to net cash used by operating activities:    
Depreciation 531 552
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D. 4,762,103 3,411,767
Changes in operating assets and liabilities    
Accounts payable (35,638) (22,609)
Accrued liabilities 10,365 (12)
NET CASH USED BY OPERATING ACTIVITIES (388,541) (399,848)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 387,199 398,829
NET CASH PROVIDED BY FINANCING ACTIVITIES 387,199 398,829
NET DECREASE IN CASH (1,342) (1,019)
CASH AT BEGINNING OF PERIOD 17,476 18,122
CASH AT END OF PERIOD $ 16,134 $ 17,103

v2.4.0.6
BASIS OF PRESENTATION
9 Months Ended
Nov. 30, 2011
BASIS OF PRESENTATION  
BASIS OF PRESENTATION

NOTE A.      BASIS OF PRESENTATION

 

The financial statements of Burzynski Research Institute, Inc., a Delaware corporation (the “Company”), include expenses incurred directly by S.R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) within his medical practice, related to the conduct of U.S. Food and Drug Administration (“FDA”) approved clinical trials for Antineoplaston drugs used in the treatment of cancer.  These expenses have been reported as research and development costs and as additional paid-in capital.  Cash contributions received from Dr. Burzynski have also been reported as additional paid-in capital, which are used to fund general operating expenses. Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements.  Dr. Burzynski is the President, Chairman of the Board and owner of over 80% of the outstanding stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons,” which he has licensed to the Company.

 

The Company and Dr. Burzynski have entered into various agreements which provide the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once an Antineoplaston drug is approved for sale by the FDA.

 

The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer.  The Company is currently conducting clinical trials on various Antineoplastons in accordance with FDA regulations. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted. In September 2004, the Company announced that the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of brainstem glioma.  During 2008, the FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of all gliomas.

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2011 and February 28, 2011, results of operations for the three and nine months ended November 30, 2011 and 2010, and cash flows for the nine months ended November 30, 2011 and 2010.  All adjustments are of a normal recurring nature.  The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year.  These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2011.

v2.4.0.6
BALANCE SHEETS (Parenthetical) (USD $)
Nov. 30, 2011
Feb. 28, 2011
BALANCE SHEETS    
Property and equipment, accumulated depreciation (in dollars) $ 18,826 $ 18,295
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 131,448,444 131,448,444
Common stock, shares outstanding 131,448,444 131,448,444

v2.4.0.6
Document and Entity Information
9 Months Ended
Nov. 30, 2011
Document and Entity Information  
Entity Registrant Name BURZYNSKI RESEARCH INSTITUTE INC
Entity Central Index Key 0000724445
Document Type 10-Q
Document Period End Date Nov. 30, 2011
Amendment Flag false
Current Fiscal Year End Date --02-28
Entity Current Reporting Status Yes
Entity Filer Category Smaller Reporting Company
Entity Common Stock, Shares Outstanding 131,448,444
Document Fiscal Year Focus 2012
Document Fiscal Period Focus Q3

v2.4.0.6
STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 9 Months Ended
Nov. 30, 2011
Nov. 30, 2010
Nov. 30, 2011
Nov. 30, 2010
Operating expenses        
Research and development $ 1,764,352 $ 1,172,273 $ 4,939,748 $ 3,592,998
General and administrative 75,451 37,220 185,623 195,996
Depreciation 177 180 531 552
Total operating expenses 1,839,980 1,209,673 5,125,902 3,789,546
Net loss before provision for income tax (1,839,980) (1,209,673) (5,125,902) (3,789,546)
Provision for income tax 0   0  
NET LOSS $ (1,839,980) $ (1,209,673) $ (5,125,902) $ (3,789,546)
Loss per share information:        
Basic and diluted loss per common share (in dollars per share) $ (0.01) $ (0.01) $ (0.04) $ (0.03)
Weighted average number of common shares outstanding, basic (in shares) 131,448,444 131,448,444 131,448,444 131,448,444
Weighted average number of common shares outstanding, diluted (in shares) 131,448,444 131,448,444 131,448,444 131,448,444

v2.4.0.6
STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)
Total
Common Stock
Additional Paid-in Capital
Retained Deficit
Balance at Feb. 28, 2011 $ (51,255) $ 131,449 $ 94,260,707 $ (94,443,411)
Balance (in shares) at Feb. 28, 2011   131,448,444    
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D. 387,199   387,199  
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D. 4,762,103   4,762,103  
Net loss (5,125,902)     (5,125,902)
Balance at Nov. 30, 2011 $ (27,855) $ 131,449 $ 99,410,009 $ (99,569,313)
Balance (in shares) at Nov. 30, 2011   131,448,444    

v2.4.0.6
INCOME TAXES
9 Months Ended
Nov. 30, 2011
INCOME TAXES  
INCOME TAXES

NOTE D.      INCOME TAXES

 

The Company follows the provisions of FASB ASC 740-10, “Accounting for Uncertainty in Income Taxes.”  The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.

 

The Company recognizes interest and penalties as interest expense when they are accrued or assessed.

 

The federal income tax returns of the Company for 2010, 2009, and 2008 are subject to examination by the IRS, generally for three years after they are filed.

 

The actual provision for income tax for the three months and nine months ended November 30, 2011 and 2010, respectively, differ from the amounts computed by applying the U.S. federal income tax rate of 34% to the pretax loss as a result of the following:

 

 

 

Three Months Ended November 30,

 

 

 

2011

 

2010

 

 

 

 

 

 

 

Expected income tax benefit

 

$

(625,594

)

$

(411,289

)

Effect of expenses deducted directly by Dr. Burzynski

 

625,594

 

411,289

 

Nondeductible expenses and other adjustments

 

6,018

 

(26,672

)

Change in valuation allowance

 

(6,018

)

26,672

 

State tax

 

 

 

 

 

 

 

 

 

Income tax expense

 

$

 

$

 

 

 

 

Nine Months Ended November 30,

 

 

 

2011

 

2010

 

 

 

 

 

 

 

Expected income tax benefit

 

$

(1,742,807

)

$

(1,288,446

)

Effect of expenses deducted directly by Dr. Burzynski

 

1,742,807

 

1,288,442

 

Nondeductible expenses and other adjustments

 

(7,955

)

(7,157

)

Change in valuation allowance

 

7,955

 

7,161

 

State tax

 

 

 

 

 

 

 

 

 

Income tax expense

 

$

 

$

 

 

At November 30, 2011, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $365,723.  The Company’s ability to utilize net operating loss carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income.  The Company has no historical earnings on which to base an expectation of future taxable income.  Accordingly, a valuation allowance for deferred tax assets has been provided.  At November 30, 2011, the Company had net operating loss carryforwards available to offset future income in the amount of $934,925, which may be carried forward and will expire if not used between 2012 and 2032 in varying amounts.